Abstract
Benzodiazepines have been officially approved for use in the management of
anxiety disorders since the 1960s. However, they have been gradually
going out of favour in preference for medications such as quetiapine, an
atypical antipsychotic. The reason for this shift is due to concerns regarding
risk of abuse, dependence, tolerance, withdrawal, sedation, cognitive impairment, psychomotor impairment and suicide-related overdose (Hirschtritt et al., 2021).
anxiety disorders since the 1960s. However, they have been gradually
going out of favour in preference for medications such as quetiapine, an
atypical antipsychotic. The reason for this shift is due to concerns regarding
risk of abuse, dependence, tolerance, withdrawal, sedation, cognitive impairment, psychomotor impairment and suicide-related overdose (Hirschtritt et al., 2021).
| Original language | English |
|---|---|
| Pages (from-to) | 1109-1110 |
| Number of pages | 2 |
| Journal | Australian and New Zealand Journal of Psychiatry |
| Volume | 55 |
| Issue number | 11 |
| Early online date | May 2021 |
| DOIs |
|
| Publication status | Published - Nov 2021 |
Keywords
- Benzodiazepine
- Anxiety Disorders
- Risk